The Wright and Harding 2015 review in the Journal of Alzheimers Disease situated the HGF/c-Met system more broadly as a candidate cognitive-research target, summarizing the receptors roles in neurogenesis, synaptic plasticity, and neuroprotection [4]
investigated the in vivo effects of intradiscal administration of osteogenic protein-1 (OP-1) and transforming growth factor-beta (TGF-) into the IVDs of rabbits
Long-Acting Amylin Agonist GUB014295 Gubra A/S (Hrsholm, Denmark), a biotech company specialized in pre-clinical contract research, initiated a phase 1 clinical trial (NCT06144684) to investigate the safety, tolerability and pharmacological properties of GUB014295 (GUBamy), a long-acting OW SC amylin agonist, in healthy volunteers [117]
Tens of millions of Americans already are, and millions more are coming, because the interest in taking ownership of your own health is the fastest-growing movement in the entire country